Ipragliflozin
Ipragliflozin is a pharmaceutical drug with 25 clinical trials. Historical success rate of 96.0%.
Success Metrics
Based on 24 completed trials
Phase Distribution
Phase Distribution
2
Early Stage
3
Mid Stage
19
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
96.0%
24 of 25 finished
4.0%
1 ended early
0
trials recruiting
25
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study to Assess the Safety and Efficacy of ASP1941 in Combination With α-glucosidase Inhibitor in Type 2 Diabetic Patients
A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Pioglitazone in Type 2 Diabetic Patients
A Study to Assess the Safety and Efficacy of ASP1941 in Combination With Dipeptidyl Peptidase-4 (DPP-4) Inhibitor in Type 2 Diabetic Patients
A Study to Assess Safety and Efficacy of ASP1941 in Combination With Nateglinide in Type 2 Diabetic Patients
A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Metformin in Type 2 Diabetic Patients
Clinical Trials (25)
A Study to Assess the Safety and Efficacy of ASP1941 in Combination With α-glucosidase Inhibitor in Type 2 Diabetic Patients
A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Pioglitazone in Type 2 Diabetic Patients
A Study to Assess the Safety and Efficacy of ASP1941 in Combination With Dipeptidyl Peptidase-4 (DPP-4) Inhibitor in Type 2 Diabetic Patients
A Study to Assess Safety and Efficacy of ASP1941 in Combination With Nateglinide in Type 2 Diabetic Patients
A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Metformin in Type 2 Diabetic Patients
A Study to Assess the Long-term Safety and Efficacy of ASP1941 in Japanese Diabetic Patients
A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Sulfonylurea in Type 2 Diabetic Patients
A Study to Assess the Efficacy and Safety of ASP1941 in Japanese Type 2 Diabetes Patients
A Study to Evaluate the Effect of ASP1941 in Adult Patients With Type 2 Diabetes Mellitus
A Study to Evaluate the Effect of ASP1941 in Combination With Metformin in Adult Patients With Type 2 Diabetes Mellitus
A Study of ASP1941 in Participants With Type 2 Diabetes Mellitus
A Study of ASP1941 in Combination With Insulin in Patients With Type 1 Diabetes Mellitus
Study of Ipragliflozin in Patients With Type 2 Diabetes Mellitus Receiving Insulin Therapy
A Study to Evaluate Long-term Safety and Efficacy of ASP1941 in Diabetes Patients
Post-Marketing Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Ipragliflozin in Combination With GLP-1 Receptor Agonists in Japanese Patients With Type 2 Diabetes Mellitus (T2DM)
A Study to Evaluate the Renal Protective Effect (Urine Albumin-to-Creatinine Ratio (UACR)), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus Patients With Albuminuria
A Study to Assess the Efficacy and Safety of Ipragliflozin in Combination With Insulin in Subjects With Type 2 Diabetes Mellitus
Specified Drug Use Results Survey of Ipragliflozin Treatment in type2 Diabetes Patients
Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and Metformin
Ipragliflozin Add-on Long-term Study in Japanese Participants With Type 2 Diabetes Mellitus on Sitagliptin (MK-0431J-849)
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 25